- Home
- CDTG vs ELEV Comparison
CDTG vs ELEV Comparison
Compare CDTG & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- ELEV
- Stock Information
- Founded
- CDTG 2012
- ELEV 2019
- Country
- CDTG China
- ELEV United States
- Employees
- CDTG N/A
- ELEV N/A
- Industry
- CDTG
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- CDTG
- ELEV Health Care
- Exchange
- CDTG NYSE
- ELEV Nasdaq
- Market Cap
- CDTG 24.5M
- ELEV 20.0M
- IPO Year
- CDTG 2024
- ELEV 2021
- Fundamental
- Price
- CDTG $0.58
- ELEV $0.31
- Analyst Decision
- CDTG
- ELEV Buy
- Analyst Count
- CDTG 0
- ELEV 6
- Target Price
- CDTG N/A
- ELEV $2.94
- AVG Volume (30 Days)
- CDTG 252.6K
- ELEV 816.1K
- Earning Date
- CDTG 05-15-2025
- ELEV 05-15-2025
- Dividend Yield
- CDTG N/A
- ELEV N/A
- EPS Growth
- CDTG N/A
- ELEV N/A
- EPS
- CDTG 0.14
- ELEV N/A
- Revenue
- CDTG $29,765,205.00
- ELEV N/A
- Revenue This Year
- CDTG N/A
- ELEV N/A
- Revenue Next Year
- CDTG N/A
- ELEV N/A
- P/E Ratio
- CDTG $4.50
- ELEV N/A
- Revenue Growth
- CDTG N/A
- ELEV N/A
- 52 Week Low
- CDTG $0.52
- ELEV $0.22
- 52 Week High
- CDTG $4.64
- ELEV $4.33
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- ELEV 45.83
- Support Level
- CDTG N/A
- ELEV $0.30
- Resistance Level
- CDTG N/A
- ELEV $0.32
- Average True Range (ATR)
- CDTG 0.00
- ELEV 0.03
- MACD
- CDTG 0.00
- ELEV -0.00
- Stochastic Oscillator
- CDTG 0.00
- ELEV 40.10
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.